IQGAP2 Inhibitors

IQGAP2 inhibitors are compounds that may reduce the function of IQGAP2 by various mechanisms. They may act by directly interfering with the protein interactions essential for IQGAP2's scaffolding functions, such as ML-141 and NSC23766, which inhibit small GTPases that interact with IQGAP2. By blocking these interactions, the inhibitors could impair IQGAP2's ability to influence cell signaling and cytoskeletal dynamics.

Other inhibitors may affect the actin cytoskeleton, which is central to IQGAP2's function. Compounds like blebbistatin, CK-636, and latrunculin A can disrupt actin polymerization and myosin-II activity, leading to altered cell shape and motility where IQGAP2 is involved. Additionally, inhibitors of signaling pathways like PD98059, LY294002, and Y-27632 might indirectly modulate the activity of IQGAP2 by altering the kinase activities that influence cytoskeletal organization and dynamics. Furthermore, compounds that affect the stability of actin filaments, such as cytochalasin D and swinholide A, could also serve as indirect inhibitors of IQGAP2 by disrupting its interaction with the actin cytoskeleton. In neuronal cells, compounds like securinine that modulate neurotransmitter signaling might also affect IQGAP2 function indirectly.